Sugi Predict

Sugi Predict / Compounds / SCHEMBL21361567

SCHEMBL21361567

SCHEMBL21361567

C[C@H]1CN(S(=O)(=O)c2ccc(N(C)C)cc2)CCCN(CC2CCCCC2)CCCN(S(=O)(=O)N2CCN(c3ccccc3Cl)CC2)C1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.44
▸ HSD11B1 P28845 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ OPRK1 P41145 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MCOLN3 Q8TDD5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361498 0.92 LMNA (0.43) NPSR1HSD11B1ALDH1A1LMNAOPRK1
SCHEMBL21361499 0.91 ALDH1A1 (0.43) NPSR1HSD11B1ALDH1A1LMNASMN1; SMN2
SCHEMBL23102253 0.90 NPSR1 (0.40) NPSR1HSD11B1ALDH1A1LMNAOPRK1
SCHEMBL23102067 0.90 ALDH1A1 (0.46) ALDH1A1LMNATSHRKMT2ADRD2
SCHEMBL21361409 0.89 SMN1; SMN2 (0.45) NPSR1HSD11B1LMNAOPRK1SMN1; SMN2
SCHEMBL24755914 0.88 NPSR1 (0.45) NPSR1ALDH1A1LMNAOPRK1SMN1; SMN2
SCHEMBL21361525 0.88 CD4 (0.44) NPSR1HSD11B1ALDH1A1LMNAOPRK1
SCHEMBL23102269 0.87 HTR1A (0.40) NPSR1HSD11B1ALDH1A1LMNAKMT2A
SCHEMBL21361502 0.87 MEN1 (0.48) NPSR1ALDH1A1LMNASMN1; SMN2L3MBTL1
SCHEMBL23102240 0.86 NPSR1 (0.39) NPSR1ALDH1A1LMNAOPRK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 — — EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 — — EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 — — US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 — — US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 — — US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G NPSR1 2606/4885HSD11B1 258/4885ALDH1A1 4848/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G NPSR1 2535/4885HSD11B1 290/4885ALDH1A1 4834/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G NPSR1 2424/4885HSD11B1 274/4885ALDH1A1 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.